Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 10/20 | 0.60 |
| ▸ | TPSD1 | Q9BZJ3 | 10/20 | 0.60 |
| ▸ | TPSG1 | Q9NRR2 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333598 | 0.91 | TPSAB1 (0.51) | TPSAB1TPSD1TPSG1F13A1TGM2 | |
| SCHEMBL3336619 | 0.89 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1KDM4EALDH1A1 | |
| SCHEMBL3336069 | 0.85 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1ALDH1A1KMT2A | |
| SCHEMBL3336566 | 0.85 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1ALDH1A1KMT2A | |
| SCHEMBL4697607 | 0.82 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1ALDH1A1MAPT | |
| SCHEMBL3335635 | 0.81 | TPSAB1 (0.41) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL3335469 | 0.80 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1KDM4E | |
| SCHEMBL3332397 | 0.80 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1KDM4E | |
| SCHEMBL3339769 | 0.73 | TPSAB1 (0.59) | TPSAB1TPSD1TPSG1ALDH1A1P2RY1 | |
| SCHEMBL8257538 | 0.73 | TPSAB1 (0.68) | TPSAB1TPSD1TPSG1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.